US Edition
Published • loading... • Updated
Gilead Acquisition: Nearly Eight Billion Us Dollars for Promising Cell Therapies
Summary by Deutsches Ärzteblatt
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Foster City – It's neither new nor surprising that billions are paid for acquisitions in the pharmaceutical industry. Nevertheless, a planned purchase by Gilead Sciences warrants a closer look. The US pharmaceutical giant intends to acquire the US biotech company Arcellx for $7.8 billion (€6.7 billion), according to its own statements. The...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
